California State Teachers Retirement System Sells 7,931 Shares of Exelixis, Inc. (NASDAQ:EXEL)

California State Teachers Retirement System trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 3.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 241,973 shares of the biotechnology company's stock after selling 7,931 shares during the quarter. California State Teachers Retirement System owned about 0.09% of Exelixis worth $8,058,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Balyasny Asset Management L.P. raised its stake in shares of Exelixis by 1.9% during the fourth quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company's stock worth $573,000 after buying an additional 317 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its position in shares of Exelixis by 4.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company's stock worth $235,000 after purchasing an additional 330 shares during the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of Exelixis by 0.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company's stock worth $1,937,000 after purchasing an additional 354 shares during the period. Principal Securities Inc. increased its holdings in Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 373 shares during the last quarter. Finally, V Square Quantitative Management LLC increased its holdings in Exelixis by 37.3% in the fourth quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 425 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Exelixis Stock Up 0.5%

Shares of EXEL stock traded up $0.21 on Wednesday, reaching $42.88. The company had a trading volume of 554,180 shares, compared to its average volume of 2,320,055. The stock has a market capitalization of $11.69 billion, a PE ratio of 24.23, a price-to-earnings-growth ratio of 1.13 and a beta of 0.28. The business's 50-day moving average is $38.68 and its 200 day moving average is $36.49. Exelixis, Inc. has a one year low of $21.36 and a one year high of $48.85.

Analysts Set New Price Targets

EXEL has been the subject of several research analyst reports. Barclays boosted their price target on shares of Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a report on Thursday, February 13th. Citigroup raised their target price on shares of Exelixis from $45.00 to $56.00 and gave the company a "buy" rating in a research report on Thursday, May 15th. Royal Bank of Canada reiterated an "outperform" rating and set a $40.00 price objective on shares of Exelixis in a research note on Wednesday, May 14th. Morgan Stanley reissued an "overweight" rating and issued a $47.00 price objective (up previously from $40.00) on shares of Exelixis in a report on Wednesday, May 14th. Finally, JMP Securities restated a "market outperform" rating and set a $41.00 target price on shares of Exelixis in a report on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Exelixis currently has a consensus rating of "Moderate Buy" and an average target price of $38.94.

Insider Buying and Selling at Exelixis

In related news, EVP Dana Aftab sold 1,508 shares of the firm's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $39.00, for a total transaction of $58,812.00. Following the completion of the transaction, the executive vice president now directly owns 693,181 shares of the company's stock, valued at $27,034,059. This trade represents a 0.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Patrick J. Haley sold 126,383 shares of the company's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $47.96, for a total value of $6,061,328.68. Following the completion of the sale, the executive vice president now owns 446,459 shares in the company, valued at $21,412,173.64. The trade was a 22.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 431,740 shares of company stock worth $19,894,998. 2.85% of the stock is currently owned by insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.